148 related articles for article (PubMed ID: 12213220)
41. Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells.
Sun SY; Yue P; Hong WK; Lotan R
Cancer Res; 2000 Nov; 60(22):6537-43. PubMed ID: 11103825
[TBL] [Abstract][Full Text] [Related]
42. Caveolin-1 phosphorylation in human squamous and epidermoid carcinoma cells: dependence on ErbB1 expression and Src activation.
Kim YN; Dam P; Bertics PJ
Exp Cell Res; 2002 Oct; 280(1):134-47. PubMed ID: 12372346
[TBL] [Abstract][Full Text] [Related]
43. Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug.
Mitsiades N; Poulaki V; Mitsiades CS; Anderson KC
Expert Opin Investig Drugs; 2001 Jun; 10(6):1075-84. PubMed ID: 11772236
[TBL] [Abstract][Full Text] [Related]
44. Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.
Liu H; Li L; Li XQ; Liu XJ; Zhen YS
Anticancer Drugs; 2009 Jan; 20(1):41-9. PubMed ID: 19342999
[TBL] [Abstract][Full Text] [Related]
45. Carboplatin induces Fas (APO-1/CD95)-dependent apoptosis of human tongue carcinoma cells: sensitization for apoptosis by upregulation of FADD expression.
Mishima K; Nariai Y; Yoshimura Y
Int J Cancer; 2003 Jul; 105(5):593-600. PubMed ID: 12740905
[TBL] [Abstract][Full Text] [Related]
46. Epidermal growth factor-dependent dissociation of CrkII proto-oncogene product from the epidermal growth factor receptor in human glioma cells.
Katayama H; Hashimoto Y; Kiyokawa E; Nakaya M; Sakamoto A; Machinami R; Kurata T; Mochizuki N; Matsuda M
Jpn J Cancer Res; 1999 Oct; 90(10):1096-103. PubMed ID: 10595738
[TBL] [Abstract][Full Text] [Related]
47. Involvement of cytochrome c and caspases in apoptotic cell death of human submandibular gland ductal cells induced by concanamycin A.
Aiko K; Tsujisawa T; Koseki T; Hashimoto S; Morimoto Y; Amagasa T; Nishihara T
Cell Signal; 2002 Aug; 14(8):717-22. PubMed ID: 12020772
[TBL] [Abstract][Full Text] [Related]
48. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity.
Mitsiades N; Yu WH; Poulaki V; Tsokos M; Stamenkovic I
Cancer Res; 2001 Jan; 61(2):577-81. PubMed ID: 11212252
[TBL] [Abstract][Full Text] [Related]
49. Proteasome inhibitors induce Fas-mediated apoptosis by c-Myc accumulation and subsequent induction of FasL message in human glioma cells.
Tani E; Kitagawa H; Ikemoto H; Matsumoto T
FEBS Lett; 2001 Aug; 504(1-2):53-8. PubMed ID: 11522296
[TBL] [Abstract][Full Text] [Related]
50. Phosphatidylinositol 3-kinase/Akt positively regulates Fas (CD95)-mediated apoptosis in epidermal Cl41 cells.
Lu B; Wang L; Stehlik C; Medan D; Huang C; Hu S; Chen F; Shi X; Rojanasakul Y
J Immunol; 2006 Jun; 176(11):6785-93. PubMed ID: 16709838
[TBL] [Abstract][Full Text] [Related]
51. Polarization of the vacuolar adenosine triphosphatase delineates a transition to high-grade pancreatic intraepithelial neoplasm lesions.
Sreekumar BK; Belinsky GS; Einwachter H; Rhim AD; Schmid R; Chung C
Pancreas; 2014 Nov; 43(8):1256-63. PubMed ID: 25072283
[TBL] [Abstract][Full Text] [Related]
52. Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor.
Huang YT; Hwang JJ; Lee PP; Ke FC; Huang JH; Huang CJ; Kandaswami C; Middleton E; Lee MT
Br J Pharmacol; 1999 Nov; 128(5):999-1010. PubMed ID: 10556937
[TBL] [Abstract][Full Text] [Related]
53. Silencing of secretory clusterin sensitizes NSCLC cells to V-ATPase inhibitors by downregulating survivin.
Kim YS; Jin HO; Hong SE; Song JY; Hwang CS; Park IC
Biochem Biophys Res Commun; 2018 Jan; 495(2):2004-2009. PubMed ID: 29253572
[TBL] [Abstract][Full Text] [Related]
54. Lactoferrin selectively triggers apoptosis in highly metastatic breast cancer cells through inhibition of plasmalemmal V-H+-ATPase.
Pereira CS; Guedes JP; Gonçalves M; Loureiro L; Castro L; Gerós H; Rodrigues LR; Côrte-Real M
Oncotarget; 2016 Sep; 7(38):62144-62158. PubMed ID: 27556694
[TBL] [Abstract][Full Text] [Related]
55. Inhibitors of vacuolar-type H(+)-ATPase suppresses proliferation of cultured cells.
Manabe T; Yoshimori T; Henomatsu N; Tashiro Y
J Cell Physiol; 1993 Dec; 157(3):445-52. PubMed ID: 8253855
[TBL] [Abstract][Full Text] [Related]
56. Regulation of endothelial signaling and migration by v-ATPase.
Rath S; Liebl J; Fürst R; Vollmar AM; Zahler S
Angiogenesis; 2014 Jul; 17(3):587-601. PubMed ID: 24254321
[TBL] [Abstract][Full Text] [Related]
57. Hygrolidin induces p21 expression and abrogates cell cycle progression at G1 and S phases.
Kawada M; Usami I; Ohba S; Someno T; Kim J; Hayakawa Y; Nose K; Ishizuka M
Biochem Biophys Res Commun; 2002 Oct; 298(1):178-83. PubMed ID: 12379237
[TBL] [Abstract][Full Text] [Related]
58. Concanamycin A, the specific inhibitor of V-ATPases, binds to the V(o) subunit c.
Huss M; Ingenhorst G; König S; Gassel M; Dröse S; Zeeck A; Altendorf K; Wieczorek H
J Biol Chem; 2002 Oct; 277(43):40544-8. PubMed ID: 12186879
[TBL] [Abstract][Full Text] [Related]
59. Involvement of Na+/H+ exchangers in induction of cyclooxygenase-2 by vacuolar-type (H+)-ATPase inhibitors in RAW 264 cells.
Kamachi F; Yanai M; Ban HS; Ishihara K; Hong J; Ohuchi K; Hirasawa N
FEBS Lett; 2007 Oct; 581(24):4633-8. PubMed ID: 17825820
[TBL] [Abstract][Full Text] [Related]
60. Vacuolar-ATPase Inhibition Blocks Iron Metabolism to Mediate Therapeutic Effects in Breast Cancer.
Schneider LS; von Schwarzenberg K; Lehr T; Ulrich M; Kubisch-Dohmen R; Liebl J; Trauner D; Menche D; Vollmar AM
Cancer Res; 2015 Jul; 75(14):2863-74. PubMed ID: 26018087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
